Incyte's atopical dermatitis cream delayed

The US FDA needs more time for its review of a new cream for the treatment of atopical dermatitis from the company Incyte. This delay could benefit Leo Pharma.

Photo: Andrew Kelly/REUTERS / X02844

It will be another three months before the US Food and Drug Administration (FDA) is ready to give its verdict on the drug ruxolitinib from Incyte. The review period for the drug ruxolitinib has been extended until Sept. 21, according a company press release.

Ruxolitinib is administered as a topical treatment for atopical dermatitis, and it is in the class of drugs known as JAK-inhibitors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs